Scotland · NHS Scotland MSAN
Discontinuation of lixisenatide (Lyxumia®) 20micrograms/0.2ml solution for
MSAN(2023)26 · Level 2 · issued 29 Sep 2023
What the notice states
The supply position for each affected product, as recorded in the notice — read the full signed PDF above for the clinical advice and actions.
| Product | Position | Resupply |
|---|---|---|
| Discontinuation of lixisenatide (Lyxumia®) 20micrograms/0.2ml solution for | Discontinued | — |
| devices are being discontinued and stock will be exhausted by w/c 18th December 2023. | Discontinued | — |
| Sanofi – discontinuation notification - Lyxumia | Discontinued | — |
| Registration for access to the website is available to UK healthcare professionals and | Available | — |
From the NHS Scotland notice PDF (linked above); dates and “valid until” text are as stated, fuzzy wording kept as written. Scotland is covered separately from England — see methodology. Not an official NHS service, and not clinical advice — follow the guidance issued to your pharmacy.